Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures.

Evolution of endoscopic extraperitoneal radical prostatectomy (EERPE): technique and outcome. Asian J Androl (2011) 0.85

Long-term oncological and functional results of extraperitoneal laparoscopic radical prostatectomy: one surgical team's experience on 1,600 consecutive cases. World J Urol (2013) 0.78

Extraperitoneal robot-assisted laparoscopic radical prostatectomy: a single-center experience beyond the learning curve. World J Urol (2012) 0.77

A systematic review and meta-analysis of comparative studies on the efficacy of extended pelvic lymph node dissection in patients with clinically localized prostatic carcinoma. J Cancer Res Clin Oncol (2013) 0.77

Clinical value of extended pelvic lymph node dissection in patients subjected to radical prostatectomy. Wideochir Inne Tech Maloinwazyjne (2014) 0.77

Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. World J Urol (2011) 0.77

Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP): long-term results. World J Urol (2012) 0.76

Oncologic outcomes of asian men with clinically localized prostate cancer after extraperitoneal laparoscopic radical prostatectomy: a single-institution experience. Prostate Cancer (2010) 0.75

Effectiveness of postgraduate training for learning extraperitoneal access for robot-assisted radical prostatectomy. J Endourol (2011) 0.75

Evaluating PSA Density as a Predictor of Biochemical Failure after Radical Prostatectomy: Results of a Prospective Study after a Median Follow-Up of 36 Months. ISRN Urol (2013) 0.75

Laparoscopic Radical Prostatectomy Alone or With Laparoscopic Herniorrhaphy. JSLS (2016) 0.75

Dorsal vein complex preserving technique for intrafascial nerve-sparing laparoscopic radical prostatectomy. Int J Urol (2012) 0.75

Editorial comment on: oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures. Eur Urol (2009) 0.75

Midterm oncological outcome and clinicopathological characteristics of anterior prostate cancers treated by endoscopic extraperitoneal radical prostatectomy. World J Urol (2013) 0.75

Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43

Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol (2013) 3.35

Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92

Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J Urol (2009) 2.77

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48

Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45

Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41

Apoptosis and effects of intracavernous bone marrow cell injection in a rat model of postprostatectomy erectile dysfunction. Eur Urol (2008) 2.38

Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37

Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30

Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26

Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2007) 2.19

Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol (2011) 2.19

Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control--a literature review. Urology (2010) 2.19

Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15

Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology (2012) 2.13

Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol (2007) 2.10

Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09

Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03

Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87

Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol (2009) 1.83

Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol (2010) 1.82

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol (2009) 1.79

A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77

Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate (2009) 1.73

Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria? J Urol (2009) 1.73

Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol (2012) 1.69

Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68

Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res (2007) 1.68

Modified supine percutaneous nephrolithotomy for large kidney and ureteral stones: technique and results. Eur Urol (2011) 1.58

External validation of the updated partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys (2008) 1.58

Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol (2012) 1.57

Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol (2010) 1.56

The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol (2009) 1.54

Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int (2013) 1.53

Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study. Int J Urol (2013) 1.51

The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. Eur Urol (2011) 1.50

Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate (2011) 1.49

ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol (2012) 1.49

Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. BJU Int (2014) 1.49

Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int (2014) 1.48

Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology (2013) 1.45

Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol (2012) 1.43

Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol (2011) 1.42

Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther (2010) 1.42

International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. Int J Urol (2015) 1.41